Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01427946 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01427946 is a Phase 1 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT01427946, a Phase 1 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).
Interventions
- DRUG Everolimus
- DRUG IPI-504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01427946
The ClinicalTrials.gov registry entry for NCT01427946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01427946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01427946 about?
NCT01427946 is a clinical study titled "Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer". Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).
What is the current status of trial NCT01427946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2011-07. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01427946?
The interventions under investigation include: Everolimus (DRUG), IPI-504 (DRUG).
Who is sponsoring clinical trial NCT01427946?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.